NEW YORK, Dec. 28, 2025, 2:50 p.m. ET — U.S. stock market closed (Sunday).
Pfizer Inc. (NYSE: PFE) heads into the final week of 2025 with its shares hovering in the mid-$20s — a level Wall Street has increasingly framed as a “show-me” zone for investors who want evidence that Pfizer can navigate the post-COVID comedown and looming patent expirations while rebuilding growth through oncology and obesity-focused deals.
With U.S. exchanges closed for the weekend, the most actionable information for investors is where Pfizer last finished the regular session, what (limited) fresh weekend reading emerged over the past 24–48 hours, and which near-term catalysts could matter most when trading resumes Monday.
Pfizer stock price today: where PFE last traded before the weekend
Pfizer shares last closed Friday at $25.09, after trading between $24.92 and $25.11 in the session, according to Pfizer’s investor relations quote page.
Volume was about 21.6 million shares, reflecting the lighter activity that often shows up around year-end and holiday-shortened stretches.
In after-hours trading Friday, Pfizer was indicated around $25.08 (data as published by Yahoo Finance’s historical quote page), essentially flat into the weekend.
Pfizer’s 52-week range has been roughly $20.92 to $27.69, putting the stock about 9% below its 52-week high and about 20% above its 52-week low.
The broader market backdrop: year-end strength, light volume, and what that means for “defensive” names
Heading into the last trading sessions of 2025, Reuters reported investors are watching whether the S&P 500 can push toward the 7,000 milestone as the market looks to finish a strong year — while also warning that light trading volumes can exaggerate moves and that key macro events (including Federal Reserve minutes due in the coming week) could still shake sentiment.
That context matters for Pfizer because healthcare has frequently been cited as part of the market’s rotation beyond mega-cap tech, and Pfizer remains a high-dividend, mega-cap pharmaceutical name that can trade like a “value/defensive” proxy during volatility — even as its company-specific fundamentals remain the dominant driver.
What’s new in the last 24–48 hours: headlines and weekend reads on Pfizer stock
There were no major Pfizer corporate press releases dated within the last two days on the company’s investor news feeds (the latest listed items were mid-December).
Instead, the most visible Pfizer stock coverage over the past 24–48 hours skewed toward market commentary and screening-style articles:
1) “Discount” and contrarian interest shows up again — but with dividend caution
In a Dec. 27 commentary piece, The Motley Fool grouped Pfizer with other out-of-favor drugmakers as “discount” candidates, calling Pfizer “probably the riskiest option” among its picks largely because the dividend yield looks especially high and the payout ratio is above 100% in its framing — a reminder that yield alone can be a double-edged signal. The Motley Fool
The same piece also argued Pfizer is best viewed as a “turnaround” story and pointed to the company’s push to rebuild its obesity pipeline through deals. The Motley Fool+1
2) Zacks/FINVIZ: “Trending stock” focus on estimate revisions and near-term expectations
A Dec. 26 Zacks-authored article syndicated on FINVIZ highlighted Pfizer as a frequently watched ticker and emphasized analyst estimate revisions as a key driver of near-term direction. The piece cited expectations for $0.58 EPS in the current quarter (with a year-over-year decline) and described Pfizer as a Zacks Rank #3 (Hold), alongside a favorable valuation style score in its framework.
3) A 13F-driven note flagged institutional position trimming
A MarketBeat “instant alert” published Dec. 27 focused on a Form 13F disclosure, saying Meyer Handelman Co. trimmed its Pfizer stake by about 3.3% in the cited filing period. This type of headline can add color around positioning but typically doesn’t move a mega-cap on its own without broader confirmation across multiple institutions or a fresh catalyst. MarketBeat
The bigger story still driving Pfizer stock: 2026 guidance, the patent cliff, and “proof of growth”
Even though the most recent heavyweight headlines are earlier than the last 48 hours, they remain the center of gravity for Pfizer’s stock narrative.
Pfizer’s 2026 outlook: lower COVID revenue, LOE pressure, and a focus on “core” growth
On Dec. 16, Pfizer issued full-year 2026 guidance and revised its 2025 revenue outlook. Pfizer guided to:
- 2026 revenue:$59.5B to $62.5B
- 2026 adjusted diluted EPS:$2.80 to $3.00
- 2025 revenue: revised to approximately $62.0B (from a prior range)
- 2025 adjusted diluted EPS: reaffirmed at $3.00 to $3.15
Pfizer also laid out major mechanical headwinds: it expects about $1.5B less from COVID-19 products in 2026 versus 2025 and about a $1.5B negative impact from products losing exclusivity — while aiming for roughly 4% operational revenue growth at the midpoint when excluding COVID and LOE products.
Analysts and executives: why the mid-$20s range has become a “debate zone”
Reuters’ Dec. 16 analysis captured the tension that has kept Pfizer pinned in the mid-$20s despite periodic rallies. Bernstein analyst Courtney Breen was quoted saying the stock is “unlikely to break out of its current mid-20s price range until investors are convinced of a growth trajectory.” Reuters
The same Reuters report also cited JPMorgan analyst Chris Schott suggesting Pfizer’s “core” guidance was slightly above expectations and that “modest EPS upside” could emerge through the year via cost management and restructuring execution. Reuters
Pfizer CFO Dave Denton told Reuters the company sees its growth being underpinned by acquisitions and the pipeline as it looks toward a return to growth later in the decade.
Pipeline and deal engine: obesity and oncology remain the bull case
For investors trying to handicap Pfizer’s next chapter, two strategic pillars dominate:
Obesity: Metsera acquisition adds clinical-stage candidates
Pfizer completed its acquisition of Metsera in November, describing it as a step to expand Pfizer’s Internal Medicine portfolio and to compete in obesity and cardiometabolic diseases. Pfizer said Metsera brings multiple candidates, including MET-097i (a weekly and monthly injectable GLP‑1 receptor agonist “about to begin Phase 3”), an oral GLP‑1 candidate in Phase 1, and other programs. Pfizer
GLP‑1 partnerships: China distribution deal adds another route (pending approvals)
Pfizer has also pursued partnership routes to bolster its obesity strategy. Reuters reported earlier in December that Pfizer struck a deal with China’s YaoPharma related to an obesity drug, underscoring how aggressively large pharma is competing for GLP‑1 exposure.
Oncology: Seagen integration remains central to the long-term narrative
While not new this weekend, Pfizer’s Seagen acquisition remains a core piece of the “rebuild growth” thesis, and it is frequently referenced in market commentary as the company tries to replace fading COVID-era cash flows with durable specialty medicine revenues. Reuters+1
Wall Street forecasts: where analysts see Pfizer stock heading
Consensus targets still generally imply upside from the mid-$20s — but with notable disagreement on the slope of Pfizer’s turnaround.
Investing.com’s compiled analyst survey shows an overall consensus leaning Buy, with an average 12‑month price target around $28.62 (roughly 14% upside from recent levels), and a spread of targets ranging from about $23 to $36.
The same source lists recent firm-level stances/targets (examples shown on the page) such as:
- Morgan Stanley: Hold, $27 (maintained)
- BMO Capital: Buy, $30 (maintained)
- Bernstein SocGen Group: Hold, $30 (maintained)
- Guggenheim: Buy, $35 (maintained)
- Wolfe Research: Sell, $24 (maintained)
Dividend: what income investors should track before the next session
Pfizer’s dividend remains a major part of the stock’s appeal — and scrutiny.
Pfizer declared a $0.43 per share quarterly dividend payable March 6, 2026 to shareholders of record Jan. 23, 2026, and described it as the company’s 349th consecutive quarterly dividend.
At the same time, some market commentary has warned investors not to treat the elevated yield as risk-free; for example, The Motley Fool highlighted payout-ratio concerns in its recent discussion of Pfizer as a turnaround/dividend idea.
Risks still in focus: safety headlines, pricing pressure, and the “patent cliff”
Investors heading into Monday are still weighing several risk channels that have repeatedly pressured Pfizer’s multiple:
- Drug/pipeline safety headlines: Reuters reported in late December that a patient died after receiving Pfizer’s hemophilia therapy Hympavzi in a long-term study, though Pfizer said it did not anticipate an overall safety impact based on current knowledge and collected data to date.
- Pricing and margin pressures: Reuters reported Pfizer cited margin pressure tied to lower COVID sales, expected price cuts/discounts, and other factors as part of the bumpy outlook described for 2026 and beyond.
- Loss of exclusivity (LOE): Pfizer itself has highlighted LOE as a material 2026 headwind in its guidance framework, reinforcing that execution against the pipeline is central.
What Pfizer investors should know before Monday’s open
With the market closed, here are the practical items investors will be watching into the next session:
- Macro catalysts can still swing “defensive” healthcare
Reuters flagged that Fed meeting minutes in the coming week could shape rate expectations, and that thin year-end trading can magnify moves. If macro volatility picks up, high-dividend large caps like Pfizer can trade more like rate-sensitive value stocks than pure “drug pipeline” stories — at least intraday. Reuters - Watch for follow-through from Pfizer’s mid-December guidance reset
Pfizer’s 2026 outlook (revenue and EPS ranges) continues to anchor analyst models. Investors will watch whether new analyst notes adjust targets again — particularly around assumptions for COVID product run-rate, LOE impacts, and cost realignment progress. - Mark the next major corporate calendar date: Feb. 3, 2026
Pfizer has scheduled a Feb. 3, 2026 analyst call tied to its Fourth Quarter and Full Year 2025 Performance Report, to be issued that morning — likely the next clear, high-information catalyst for the stock. - Dividend timeline matters — but it’s not the only story
Income-focused investors will keep the Jan. 23, 2026 record date and March 6, 2026 payment date on their calendars, while also tracking free cash flow and capital allocation signals as Pfizer balances pipeline investment with shareholder returns.
The setup for Monday
Pfizer stock enters Monday with its price still reflecting a market that wants evidence the company can turn a heavy acquisition cycle and a reshaped pipeline into durable growth — before the patent cliff does more damage to revenue and sentiment.
The near-term story is less about weekend price action (there isn’t any) and more about whether the next batch of data points — macro prints, analyst revisions, and ultimately Pfizer’s early-February results update — can shift the narrative from “mid-$20s range-bound” to “credible growth trajectory,” the phrase that has become shorthand for what it will take to re-rate the stock. Reuters
